Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84436 trials found · Page 20 of 4222
-
Nasal spray gene therapy offers new hope for brain injury recovery
Disease control ENROLLING_BY_INVITATIONThis international study, organized by Healing Hope International, is an observational registry designed to collect real-world data on participants living with chronic hypoxic ischemic encephalopathy (HIE) who receive an emerging intranasal gene therapy based on the AAV9-PHP.eB v…
Sponsor: Healing Hope International • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for Tough-to-Treat throat cancer: adding drug to standard therapy
Disease control Not yet recruitingThis trial aimed to evaluate the efficacy of anlotinib hydrochloride combined with benmelstobart, induction chemotherapy, and concurrent chemoradiotherapy (IC+CCRT), versus a regimen of benmelstobart plus IC+CCRT, in patients with high-risk locoregionally advanced nasopharyngeal …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Race against time: new hope for 'Missed Window' stroke patients
Disease control Not yet recruitingTo verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.
Phase: PHASE3 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Brain cell transplants aim to restore movement in Parkinson's patients
Disease control Not yet recruitingParkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments primarily manage symptoms but do not halt or reverse neuronal loss. Cellular repl…
Phase: PHASE1 • Sponsor: iCamuno Biotherapeutics Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New immune cell therapy targets stubborn lymphoma
Disease control Not yet recruitingThis clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
CRISPR Gene-Editing trial seeks to supercharge immune cells against incurable blood cancer
Disease control Recruiting nowThis phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells (1XX BCMA CAR-T cells) in treating patients with multiple…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for deadly pancreatic cancer: experimental drug enters final testing phase
Disease control Not yet recruitingPancreatic cancer, which stands as one of the most lethal malignancies and a leading cause of cancer-related deaths globally, poses a significant challenge to human health worldwide. However, standard chemotherapeutic regimens show limited effectiveness in advanced pancreatic can…
Phase: PHASE3 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New hope for women with Tough-to-Treat cervical cancer
Disease control Not yet recruitingThis is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior…
Phase: PHASE3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Could a weekly shot turn back your biological clock?
Disease control Recruiting nowThis pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg s…
Phase: PHASE2 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New Two-Pronged attack on advanced breast cancer enters major trial
Disease control Recruiting nowThe study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Fighting melanoma with your own immune cells: new trial challenges chemotherapy
Disease control Not yet recruitingThis is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced melanoma. A total of 90 participants are planned to b…
Phase: PHASE2 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New Two-Drug attack on Tough-to-Treat breast cancer enters final testing phase
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Fighting lung cancer with your own immune cells
Disease control Not yet recruitingAfter receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Ph…
Phase: PHASE2 • Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
One-Time gene therapy aims to free patients from sickle cell pain crises
Disease control Recruiting nowThe purpose of this study is to evaluate the Safety and Efficacy of DREAM01, a gene therapy for Sickle Cell Disease (SCD). The therapy consists of transplanting autologous CD34+ cells transduced ex vivo with a bifunctional lentiviral vector expressing βAS3m-globin and an anti-βS …
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
Radiation, drugs, then surgery: a triple attack on tough head and neck cancers
Disease control Not yet recruitingThe objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free survival rate and overall survival rate in patients d…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 06, 2026 14:06 UTC
-
Army tests lifeline program to stop soldier suicides after hospital discharge
Disease control Recruiting nowThis study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from mili…
Phase: NA • Sponsor: Uniformed Services University of the Health Sciences • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
New weekly shot aims to help people shed pounds in major trial
Disease control Recruiting nowThe purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treat…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New combo therapy aims to wipe out tough rectal tumors before surgery
Disease control Recruiting nowWhy is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer (LARC). In recent years, with the combination of neoadj…
Phase: PHASE2, PHASE3 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Major trial aims to spare thousands from chemo side effects
Disease control Not yet recruitingThis study is a Phase III non-inferiority trial targeting a specific subset of early breast cancer patients: those with HR-positive/HER2-negative, node-negative small tumors (typically ≤2cm) but who exhibit high-risk features for recurrence (such as high histological grade, high …
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Breakthrough hope for Drug-Resistant TB: shorter treatment with new pill
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug…
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC